Compare GAIA & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GAIA | GRML |
|---|---|---|
| Founded | 1988 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.9M | 29.2M |
| IPO Year | 1999 | 2022 |
| Metric | GAIA | GRML |
|---|---|---|
| Price | $1.26 | $4.01 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $3.38 | N/A |
| AVG Volume (30 Days) | 95.5K | ★ 2.3M |
| Earning Date | 11-02-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 18.18 | ★ 31.25 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,500,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 12.50 | N/A |
| 52 Week Low | $1.16 | $0.16 |
| 52 Week High | $4.48 | $18.21 |
| Indicator | GAIA | GRML |
|---|---|---|
| Relative Strength Index (RSI) | 40.37 | 40.68 |
| Support Level | $1.18 | $0.28 |
| Resistance Level | $1.47 | $7.53 |
| Average True Range (ATR) | 0.07 | 0.41 |
| MACD | -0.01 | -0.14 |
| Stochastic Oscillator | 8.33 | 17.19 |
Gaia Inc is a video streaming service and community that provides curated conscious media in primary channels; Seeking Truth provides new and enlightening perspectives for today's changing world; Transformation provides a wealth of content in the niche areas of spiritual growth, personal development, and expanded consciousness; Alternative Healing channel features content focused on food and nutrition, holistic healing, alternative and integrative medicines, and longevity, and Yoga. The company operates in a single reporting segment. Its revenues is derived from subscription fees for services related to streaming content to the members. Geographically, it derives a majority of its revenue from the United States and also has an International presence.
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.